Evaluation of HGF and Endostatin in the bone marrow of patients with multiple myeloma and the effect of peripheral blood admixture

The aim of our study was to evaluate the concentration changes in the proangiogenic hepatocyte growth factor and antiangiogenic endostatin during the sampling of large bone marrow volumes in patients with multiple myeloma.

[1]  D. Kyriakou,et al.  Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: Correlation with markers of disease activity , 2003, American journal of hematology.

[2]  H. Goldschmidt,et al.  Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion , 2001, British journal of haematology.

[3]  D. Ribatti,et al.  Bone marrow angiogenesis in patients with active multiple myeloma. , 2001, Seminars in oncology.

[4]  T. Ichinohe.  Tumor Angiogenesis and Microcirculation , 2001, International journal of hematology.

[5]  K. Wernecke,et al.  Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma , 2001, European journal of haematology.

[6]  O. Laerum,et al.  Flow cytometric measurement of DNA S‐phase in human bone marrow cells: correcting for peripheral blood contamination , 1996, European journal of haematology.

[7]  M Marusić,et al.  Relationship between differing volumes of bone marrow aspirates and their cellular composition. , 1990, Bone marrow transplantation.

[8]  T. Robak,et al.  High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment , 2003 .

[9]  F. Di Raimondo,et al.  Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. , 2000, Haematologica.